cancers was determined by the International Federation of Obstetrics and Gynaecology (FIGO) classification (FIGO News, 1989) . Sixty-two patients underwent curative resection for uterine cervical cancer and were observed for a 24-month survival rate. For these patients, immunohistochemical staining for PD-ECGF, Ki-67 and factor VIII-related antigen was carried out to analyse PD-ECGF functions related to cellular proliferation and to microvessel density and venous invasion.
Enzyme immunoassay for determination of human PD-ECGF antigen
All steps were carried out at 4°C. Tissues (wet weight 10Ð20 mg) were homogenized in HG buffer (5 mM tris-HCl, pH 7.4, 5 mM sodium chloride, 1 mM calcium chloride, 2 mM EGTA, 1 mM magnesium chloride, 2 mM dithiothreitol (DTT), 25 µg ml Ð1 aprotinin, and 25 µg ml Ð1 leupeptin) with a Polytron homogenizer (Kinematics, Luzern, Switzerland) . This suspension was centrifuged in a microfuge at 12 000 r.p.m. for 3 min to obtain the supernatant. The protein concentration of samples was measured by the method of Bradford (1976) to standardize PD-ECGF antigen levels.
PD-ECGF antigen levels in the sample were determined by the sandwich enzyme immunoassay described by Nishida et al (1996) . The levels of PD-ECGF were standardized with corresponding cellular protein concentrations.
Immunohistochemistry
For formalin-fixed paraffin-embedded tissues, 4-µm sections were cut with a microtome and dried overnight at 37°C on a silanized slide (Dako, Carpinteria, USA). Samples were deparaffinized in xylene at room temperature for 80 min and washed with a graded ethanol/water mixture and then with distilled water. The samples for PD-ECGF were soaked in phosphate-buffered saline (PBS), those for Ki-67 were soaked in a citrate buffer and then autoclaved at 121°C for 10 min, and those for factor VIII-related antigen were treated with 0.3 µg ml Ð1 trypsin in PBS at room temperature for 20 min. The protocol for a Dako LSAB2 Kit, Peroxidase (Dako) was followed for each sample. In the described procedures, mouse anti-human PD-ECGF antigen 654-1 [10 µg ml Ð1 , Nippon Roche, Kamakura, Japan (Nishida et al, 1996) ], rabbit anti-human Ki-67 antigen (10 µg ml Ð1 , Dako), and rabbit anti-factor VIII-related antigen (Zymed, San Francisco, USA) were used at dilutions of 1:100, 1:50 and 1:2 respectively. The proliferating cell population was evaluated using the Ki-67 index (Nakano and Oka, 1993) . Vascular density was evaluated with microvessel counting (Maeda et al, 1996) .
Reverse transcription polymerase chain reaction (RT-PCR) to amplify PD-ECGF mRNA
Total RNA was isolated from the cells by the acid guanidium thiocyanateÐphenolÐchloroform extraction method (Chomczynski and Sacchi, 1987) . Total RNA (3 µg) was reverse transcribed with Moloney murine leukaemia virus reverse transcriptase (MMLVRTase, 200 units, Gibco BRL, Gaithersburg, MD, USA) in a buffer of 20 mM tris-HCl, pH 8.4, 50 mM potassium chloride, 2.5 mM magnesium chloride, 0.1 mg ml Ð1 bovine serum albumin, 10 mM DTT and 0.5 mM deoxynucleotides to generate cDNAs using random hexamer (50 ng, Gibco BRL) at 37°C for 60 min. The RT reaction mixture was heated at 94°C for 5 min to inactivate MMLV-RTase.
Five cycles of PCR for PD-ECGF mRNA, consisting of denaturation for 1 min at 94°C, annealing for 1 min at 55°C, and extension for 1 min at 72°C, were carried out with reverse transcribed cDNA, 0.1 µM specific primers and Vent DNA polymerase (New England Biolabs, Beverly, MA, USA) in a buffer of 10 mM potassium chloride, 20 mM tris-HCl, pH 8.8, 10 mM diammonium sulphate, 2 mM magnesium sulphate, 0.1% Triton X-100 and 0.15 mM deoxynucleotide phosphates using the IWAKI thermal sequencer TSR-300 (Iwaki Glass, Tokyo, Japan). Additionally, 23 cycles of PCR for PD-ECGF and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as an internal standard were carried out in the same manner.
The oligodeoxynucleotides of specific primers in PCR were synthesized according to the published information on cDNA for PD-ECGF (Hagiwara et al, 1991) and GAPDH (Arcari et al, 1984) as follows: sense primer for PD-ECGF mRNA: 5′-AGTCGGATG-GCCATCAGCAT-3′ (in exon 2); antisense primer for PD-ECGF mRNA: 5′-TGGAATGCTTGTCCACAAGC-3′ (in exon 3); sense primer for GAPDH mRNA: 5′-TGAAGGTCGGAGTCAACG-GATTTGGT-3′ (in exon 2); antisense primer for GAPDH mRNA: 5′-CATGTGGGCCATGAGGTCCACCAC-3′ (in exon 8). 
Southern blot analysis for quantities of PD-ECGF mRNA expression
PCR products were applied to 1.2% agarose gel, and electrophoresis was performed at 50Ð100 V. PCR products were capillary transferred to an Immobilon transfer membrane (Millipore, Bedford, MA, USA) for 16 h. The membrane was dried at 80°C for 30 min, and was UV irradiated to tightly fix the PCR products. PCR products on the membrane were prehybridized in 1 M sodium chloride, 50 mM Tris-HCl, pH 7.6, and 1% sodium dodecyl sulphate at 42°C for 1 h, and hybridized in the same solution with the biotinylated oligodeoxynucleotide probes synthesized from the sequences of PD-ECGF and GAPDH cDNAs between the specific primers at 65°C overnight. Specific bands hybridized with the biotinylated probes were detected with Plex Luminescent Kits (Millipore), and radiographic film was exposed on the membrane at room temperature for 10 min. The quantification of Southern blot was carried out with Bio Image (Millipore, Ann Arbor, MI, USA). The intensity of specific bands was standardized with that of GAPDH mRNA.
Statistics
Survival curves were calculated using the KaplanÐMeier method and analysed with the log-rank test. The correlations between the level of PD-ECGF and microvessel count, and between the level of PD-ECGF and Ki-67 index were analysed with SpearmanÕs correlation coefficient. The levels of PD-ECGF and its mRNA were measured from three parts of the same tissue in triplicate. Statistical analysis was performed with StudentÕs t-test. Differences were considered significant when the P-value was less than 0.05.
RESULTS
Among the 62 patients who underwent curative resection and were observed for a 24-month survival rate, the prognosis of the 24 patients with high PD-ECGF (> 2500 pg mg Ð1 protein) squamous cell carcinomas was significantly (P < 0.01) worse than that of the seven patients with low PD-ECGF (< 1000 pg mg Ð1 protein) squamous cell carcinomas (Figure 1 ). There was no correlation between PD-ECGF level and the patientsÕ age (data not shown).
In the corresponding 62 tumours, immunohistochemical staining for PD-ECGF was carried out to study PD-ECGF localization in the tumours, and strength of staining was correlated with PD-ECGF levels measured by an enzyme immunoassay. As shown in Figure  2 , PD-ECGF was distributed in the surrounding interstitium near cancer cells and in the cytoplasm and nuclear compartments of the cancer cells. PD-ECGF levels correlated approximately with the strength of PD-ECGF staining.
There was a significant correlation between PD-ECGF levels and Ki-67 indices as shown in Figure 3 (y = 23.93 + 0.005x, r = 0.57, P < 0.01), and between PD-ECGF levels and microvessel counts as shown in Figure 4 (y = 14.84 + 0.005x, r = 0.58, P < 0.01). Venous invasion occurred significantly more (P < 0.01) in high PD-ECGF tumours than in low PD-ECGF tumours ( Figure 5 ).
The signal intensity curve for mRNA expression was necessary for accurate measurement of the mRNA by RT-PCR. PCR template was prepared from reverse transcribed total RNA (100 µg) from normal uterine cervices as follows: 0.25×, 0.75 µg total RNA reverse transcribed (RNA-RT); 0.5×, 1.5 µg RNA-RT; 1×, 3 µg RNA-RT; 2×, 6 µg RNA-RT; 4×, 12 µg RNA-RT; 8×, 24 µg RNA-RT; and 16×, 48 µg RNA-RT. PCR Southern blot was carried out as described in the Materials and methods section. The signal intensity curve for PD-ECGF mRNA levels ranging from 0.25× to 8× of reverse transcribed total RNA of normal uterine cervices by RT-PCR Southern blot was linear (Figure 6 ). Therefore, semiquantitative alteration of the mRNA levels was thought to be reliable.
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DISCUSSION
Newly developed capillary network formation from the original vessel is designated as neovascularization. Generally, turnover of capillary endothelial cells is extremely slow, in the order of months or years in physiological neovascularization, whereas the turnover in ovary and uterine endometrium is rapidly altered along with the ovarian cycle. The turnover with malignant transformation becomes rapid, which might contribute to the acceleration of tumour growth (Denekamp, 1984) .
Expression of tumour cell-derived angiogenic factors, basic FGF, VEGF, PD-ECGF and IL-8, may be specific for each tumour and be dependent on the process of tumour growth and spreading. For example, bladder cancers express VEGF in a three-fold excess and PD-ECGF in a 40-fold excess to the corresponding normal tissue (OÕBrien et al, 1995) . Furthermore, VEGF is dominantly expressed in superficially invasive bladder cancer cases whereas PD-ECGF is dominantly expressed in deeply invasive cases (OÕBrien et al, 1995) , indicating that the latter is a tumour advancing factor which acts mainly via angiogenic activity. The expression of basic FGF is high in uterine cervical cancers, and increases with dedifferentiation and advancing stage (Fujimoto et al, 1995) . In contrast, the expression of VEGF is high in uterine cervical cancers, especially adenocarcinoma, and decreases with advancing stage (data not yet published).
Many authors have reported that a high microvessel density correlates with poor patient prognosis in uterine cervical cancers (Kainz et al, 1995; Rutgers et al, 1995; Wiggins et al, 1995; Bremer et al, 1996; Dinh et al, 1996; Dellas et al, 1997; Obermair et al, 1998) . In the present study, the prognosis of the patients with high PD-ECGF squamous cell carcinomas was worse than those with low PD-ECGF squamous cell carcinomas, and PD-ECGF expression correlated with Ki-67 index as an indicator of cellular proliferation (Sawhney and Hall, 1992) , microvessel density and vascular invasion. Therefore, PD-ECGF might contribute to the growth of uterine cervical cancers via angiogenesis related to vascular spreading. Furthermore, the levels of PD-ECGF and its mRNA were higher in uterine cervical cancers, especially squamous cell carcinomas, than in normal uterine cervices, however they did not alter with different histopathological types among squamous cell carcinomas or with advancing stage. In immunohistochemical studies, stronger staining of PD-ECGF is found in squamous cell carcinomas than in adenocarcinomas of the uterine cervix (Tokumo et al, 1998) . The tumour cell-derived angiogenic factors basic FGF, VEGF and PD-ECGF may be uniquely expressed and dependent on the process of tumour growth and spreading, and PD-ECGF in uterine cervical cancers might play a role of basic angiogenesis in all processes of advancing of uterine cervical cancers. This indicates that 5′-deoxy-5-fluorouridine might be highly effective on squamous cell carcinomas of the uterine cervix, which possesses a high activity of thymidine phosphorylase to convert 5′-deoxy-5-fluorouridine to 5-fluorouracil (Miwa et al, 1987) regardless of the clinical stage, but related to patientsÕ prognosis, and that some angiogenic inhibitors (Ingber et al, 1990) of new capillary formation might be effective in the inhibition of tumour growth and spreading associated with angiogenesis regardless of a direct tumoral effect on cancer cells. 
